Roche to embrace new technologies early on

To Roche, scientific breakthroughs are an important source for developing and launching new treatments. Finding the right time to take in new discoveries is a challenge, says William Pao, head of early clinical research at Roche.

Roche Head of Pharma Research and Early Development (pRED) | Photo: Roche / PR

When Roche's division for early research and development enters into new partnerships, this is oftentimes a way of getting new technologies on board – be they new types of immunotherapy, gene therapy or new RNA technologies.

William Pao, who heads Roche's division for early research and development – Pharma Research and Early Development (pRED) – would like to see Roche engage more in such activities.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs